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Abstract 
Background and Aim: Transfection of DNA/RNA sequence into eukaryotic cells has a major effect on scientific 
studies. Various methods are used to transfer the DNA/RNA sequence into cells, such as lipid-based carriers as the 
available and easy procedure. Transfection with cationic lipid liposome is introduced as a simple and efficient 
procedure for monitoring the DNA/RNA sequence through gene function analysis, including fluorescence imaging 
RNA and protein expression. This study aimed to investigate the transfection efficiency and cell death through GFP 
expression in human esophageal squamous cell carcinoma (ESCC) cell line KYSE-30 using Lipofectamine 3000 
reagent.  
Methods: The pCDH-513b plasmid DNA was transfected into KYSE-30 cells using Lipofectamine 3000 in different 
concentrations of the plasmid DNA and reagent. The transfection efficiency was evaluated by fluorescence 
microscope and flow cytometry analysis to determine the percentage of GFP-expressing cells. Moreover, the 
viability and death of transfected KYSE-30 cells were evaluated using a trypan blue exclusion assay.  
Results: The transfection efficiency of KYSE-30 with Lipofectamine 3000 was increased with higher plasmid DNA 
concentration and a lower amount of Lipofectamine 3000 reagent. The Optimized concentration of 1.5 µg plasmid 
DNA and volume of one µl of lipofectamine 3000 reagents were identified for 95% transfection efficiency in the 
KYSE-30 cell line. The viability and death of transfected cells were 43% and 58% after transfection, respectively. 
Conclusion: The results indicated that Lipofectamine 3000 might not be suitable for transfection in KYSE-30 cells 
due to increased cell death. 
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Introduction 
Gene delivery is introduced as a key and valuable 
procedure for transfer a sufficient amount of genetic 
materials like nucleic acid fragments (DNAs or 
RNAs) into the target somatic or germ cells. Gene 
the transfer can help to express or suppress the gene 
of interest (GOI) in cells for the desired time to 
investigate the cellular and molecular mechanisms 
underlying gene transfer (1-3). Delivery of foreign 
DNA or RNA into the mammalian cells for genetic 
modification can have transient or stable integration 
into the host genome, depending on the type of GOI 
and how it is transmitted (4). The transient versus 
stable gene expression is defined as a quick and 
affordable process in producing recombinant 
proteins (rProteins) for a limited period (5). There 
are several beneficial factors to determine the high 
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efficiency of GOI expression in a specific tissue or 
cell and low level of death cells. Among these 
factors can mention to the expression level of GOI, 
common biosafety, desired delivery efficiency, 
cellular context, cell division,  and cell viability (6). 
There are two approaches for the delivery of foreign 
DNA or RNA into the target cells, including natural 
and artificial-mediated techniques (7).  
Non-viral gene transfer methods have led to 
transient gene expression with remarkably less 
efficiency than viral techniques. Nevertheless, new 
non-viral techniques overcome these limitations and 
improve the rProtein production efficiency (6, 8, 9). 
The non-viral methods are divided into physical and 
chemical approaches, which are generally 
dependent on the synthetic cellular barriers, like 
liposomes or nanoparticles for transferring the 
genetic material (2). The key factors in the effective 
non-viral gene transfer can refer to the type of target 
cell, the optimal cell confluency, the number of cell 
passages, existence or absence of serum in culture 
media, the optimal amount of foreign genetic 
material, the appropriate time for transfection 
complex formation, and expression of GOI in 
various cells (10). Among non-viral gene transfer 
vehicles are cationic lipids such as a liposome. 
Generally in this delivery system, positively 
charged liposome plays an important role, in 
contrast, the negative charge of both nucleic acid 
and cell membrane to overcome the electrostatic 
force of the cell membrane (10, 11). The formation 
of cationic liposome-nucleic acid complex leads to 
cellular uptake of GOI through the ionic interaction 
of the complex with the plasma membrane of the 
host cell (10, 12). The advantages of liposome-
mediated gene transfer are the high efficiency of 
gene delivery into cells, fast and convenient in the 
procedure (9). Among liposome-based transfection 
reagents can use the Lipofectamine 3000  reagent 
(13). Lipofectamine 3000 is currently considered in 
different types of cells to obtain the appropriate 
transfection efficiency; however, it demonstrates 
toxicity and apoptotic effects for some eukaryotic 
cell lines. Consequently, type and number of target 
cells, size of plasmid, and transfection reagents are 
key factors for the best yield of transfection (14).  
Hence, this study aimed to optimize the transfection 
efficiency and cell death of the chemical-based 
transfection method for human esophageal 
squamous cell carcinoma (ESCC) cell line KYSE-
30 to find the best transfection conditions. 
Therefore, Lipofectamine 3000 reagents as 
liposome-based transfection reagents were used to 
transfect KYSE-30 cells. 
Methods 
Plasmid preparation  
The pCDH-513b (System Bioscience, Palo Alto, 
CA) plasmid DNA as a green fluorescent protein 
(GFP) expression vector was applied to compare 
the transfection efficiency. The plasmid DNA 
firstly amplified in competent E. coli Stbl cells, then 
isolated and purified using the Qiagen Plasmid 
Maxiprep Kit (Qiagen, UK) according to the 
manufacturer’s instructions. The integrity of 
plasmid DNA was confirmed by electrophoresis on 
0.8% agarose gel, and the plasmid DNA was diluted 
to a final concentration of 1.5 μg/μL DNA in sterile 
water. 
Cell culture  
Human ESCC (KYSE-30) cell line was obtained 
from the Pasteur Institute Cell Bank of Iran 
(Tehran, Iran) (http://en.pasteur.ac.ir/) and cultured 
under the standard condition as follows in RPMI 
1640 medium (Biosera) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; Gibco, 
USA) with penicillin /streptomycin (100 U/mL) 
(Gibco, USA) at a humidified 37 °C incubator with 
5% CO2.  
Liposome-mediated transfection using 
Lipofectamine 3000  
All transfection procedures were performed in 24-
well plates using Lipofectamine 3000 (Invitrogen, 
USA, L3000015). There are two components in 
Lipofectamine 3000 kit, including lipofectamine 
3000 (LFN3000) and P3000 reagents. KYSE-30 
cells were seeded at a density of 0.25 × 106 cells per 
well, 20-24 hours prior to transfection in 0.5 mL of 
culture medium with 10% FBS to obtain 70-80% 
confluency at the time of transfection. 
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Firstly, to determine the efficient amount of the 
LFN3000 reagent, a mixture reaction was prepared, 
containing 1 μg plasmid DNA, 1 μL P3000 reagent, 
50 μL Opti-MEM serum-free medium (Gibco, 
USA), along with the different amount of LFN3000 
(including 0.5, 1, 1.5, and 2 μL) according to the 
manufacturer's instructions. Afterward, this cocktail 
was incubated at room temperature for 20 minutes 
to form the DNA-LFN3000 complex. Finally, the 
cell supernatant was replaced with serum and 
antibiotic-free media, and the prepared DNA-
LFN3000 complex was diluted to each well and the 
mixture was incubated at 37 °C for 36 hours. After 
determining the efficient amount of LFN3000 
reagent, the amount of 0.5, 1, and 1.5 μg plasmid 
DNA were evaluated according to the procedure 
described above to obtain optimal plasmid DNA 
concentration.  
Green fluorescence protein (GFP) assay  
The transfection efficiency was assessed through 
the expression of the integrated GFP as a reporter 
gene using wavelengths 450-490 nm ultraviolet 
light 36 hours after transfection. The GFP 
expression was visualized by an inverted 
fluorescence microscope with different 
magnifications. The transfection efficiency was 
delineated according to the percentage of GFP-
positive cells. Image analysis of GFP-positive cells 
was performed with the ImageJ software package 
(15) . Briefly, we have selected the area integrated 
intensity of image using ImageJ, then the GFP-
positive cell counting from fluorescence images in a 
final magnification of 10X microscope was 
performed randomly with four repeats using the 
ImageJ cell counter plugin. Afterward, we 
calculated the number of cells in the field of view 
(FOV) of 10X magnifying Optika microscope for a 
24-well plate as follow: 
Number of cells = [0.025 (FOV of 10X magnifying 
microscope) × (0.25 × 106) cells]/20 mm surface area 
for 24-well plate 
Finally, the number of GFP-positive cells versus the 
total cell quantity was estimated in a different 
amount of the plasmid DNA and LFN3000 as 
follow: 
% Transfection efficiency = (number of GFP-positive 
cells by ImageJ/total number of cells in FOV of 10X 
magnifying microscope) × 100 
Flow cytometry analysis  
The transfection efficiency was examined by flow 
cytometry analysis 36 hours post-transfection to 
determine the percentage of GFP-expressing cells. 
Briefly, cells were washed twice with phosphate-
buffered saline (PBS; pH = 7.4) and then 
trypsinized by 0.25 % trypsin-EDTA for 5 min at 
37 °C. The cell suspensions were centrifuged at 
2000 rpm for 6 min and the samples were detected 
by a FACSCalibur flow cytometer (BD Bioscience, 
San Jose, CA, USA) for FL1 (GFP) fluorescence. 
Then data analysis was performed using FlowJo 7.6 
software (Tree Star, Ashland, OR) to determine the 
percentage of GFP-expressing cells.  
Trypan blue exclusion test of cell viability  
The cell viability of transfected KYSE-30 cells by 
Lipofectamine 3000 reagents was evaluated using a 
trypan blue exclusion assay (16). The transfected 
cells were first trypsinized and mixed with trypan 
blue dye, then visually examined the uptake 
(stained or nonviable) and exclude (unstained or 
viable) of dye into cells (17). Although 
Lipofectamine 3000  indicated high transfection 
efficiency, perturbation due to dead cells may 
interfere with future functional studies (18). The 
percentage of nonviable and viable cells was 
calculated as follows: 
% Viable cells = (number of viable cells/ total number 
of cells) × 100 
% Dead cells = 100 - % viable cells 
Statistical analysis  
All statistical analyses were carried out using 
GraphPad Prism 5 (GraphPad Software, La Jolla, 
CA, USA). The Student T-test was applied for the 
transfection efficacy of the serially diluted 
LFN3000 and the plasmid DNA. All data was 
obtained from four biological experiments and 
values were reported as mean. The value of 
statistical significance was indicated as a P value 
less than 0.05. 
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Results 
Assessment of transfection efficiency  
Results of GFP assay after 36 hours 
The ESCC cell line KYSE-30 was transfected with 
pCDH-513b vector by different volumes of the 
LFN3000 and plasmid DNA concentrations. The 
results indicated that the most efficient GFP-
expressing cells were achieved with a volume of 
one µl among the four different LFN3000 volumes 
that select for later experiments (data not showed). 
These results suggested that the transfection 
efficiency improved in KYSE-30 cells with a 
smaller amount of LFN3000. As indicated in 
Figure 1 (A-H), green fluorescence expression 
observed in different plasmid DNA concentrations. 
The expression fluorescence intensity increased 
with the increase of plasmid DNA quantity, and the 
green fluorescence quantity of 1.5 μg of DNA was 
maximum. The number of transfected cells and the 
percentage of GFP-positive cells are demonstrated 
in Figure 2.  
Figure 1. The fluorescence microscopy images of the GFP expression profile in KYSE-30 cell transfected by Lipofectamine 3000. 
(A & B) non-transfected cells, (C & D) 0.5 μg of transfected GFP plasmid, (E & F) 1 μg of transfected GFP plasmid, (G & H) 1.5 
μg of transfected GFP plasmid with different magnification. The down panels demonstrated the corresponding merge images of the 
fluorescence images. The scale bar is 200 μm. The total of images was obtained using an inverted fluorescence microscope. 
 
 
Figure 2. The transfection efficiency was measured in KYSE-30 cells after the transfection of the pCDH-513b vector using 
Lipofectamine 3000. (A & B) the number and mean of transfected cells in different plasmid DNA concentrations, (C & D) 
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The mean of GFP-positive cells was 64.05%, 
76.07%, and 95.85% for 0.5 μg, 1 μg, and 1.5 μg of 
DNA, respectively, as depicted in Figure 2C and D. 
The highest level of GFP expression (98.3%) was 
detected with 1.5 μg plasmid DNA. Moreover, the 
average ± standard deviation (SD) of the number of 
transfected cells were 200 ± 19.91, 237 ± 10.14, and 
200 ± 4.99 cells for 0.5 μg, 1 μg, and 1.5 μg of 
DNA, respectively (Figure 2A and B). These results 
proposed that the transfection efficiency 
significantly increased in KYSE-30 cells with 
increasing higher plasmid DNA concentration (P-
value < 0.0001).  
Results of flow cytometry 
Flow cytometric analysis was used to directly 
quantify the transfection efficiency in KYSE-30 
cells (Figure 3). KYSE-30 cells without GFP 
plasmid was used as a control or unstained cells 
(Figure 3A and B).  
 
Figure 3. The transfection efficiency analysis  of pCDH-513b-transfected KYSE-30 cells using 1.5 µg of plasmid DNA. The Flow 
cytometry was used to analyze the GFP expression, (A) gating for living cells in untransfected cells (B) untransfected cells for GFP 
expressing cells (C) percentage and MFI of GFP expressing cells. FSC: forward scatter; SSC: side scatter; FL:  fluorescence scatter; 
MFI: mean fluorescence intensity. 
 
This study only analyzed the cells in a 
concentration of 1.5 μg plasmid DNA and one µl 
LFN3000 volume. The percentage of GFP-positive 
cells and mean fluorescence intensity (MFI) was 
estimated at approximately 98.3% and 7.44±7.29, 
respectively, as indicated in Figure 3C (the results 
of flow cytometry analysis are shown only for the 
concentration of 1.5 μg plasmid DNA). The flow 
cytometry data was indicated that the highest yield 
of transfection efficiency achieves with a 
concentration of 1.5 μg plasmid DNA and one µl 
LFN3000. 
Assessment of cell viability and cell death  
The viability and general health of cells were 
maintained high at the time of transfection. Trypan 
blue assay indicated that the mean ± SD of viable 
cells 36 hours after transfection were decreased 
from 43.07±1.89 for 0.5 µg to 41.60±3.86 for 
1.5 µg of the plasmid DNA (Figure 4). Moreover, 
the mean ± SD of dead cells were increased from 
57.17±2.33 for 0.5 µg to 58.40 ± 3.86 for 1.5 µg of 
the plasmid DNA. The data was exhibited that 
LFN3000 reagent induced a high relative level of 
cell death in KYSE-30 cells. As shown in Figure 4, 
the difference in cell viability and cell death in 





MFI±SD: 7.44 ± 7.29 
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Figure 4. Cell viability and cell death were measured by the trypan blue assay in KYSE-30 cells after the transfection of the pCDH-
513b vector using Lipofectamine 3000. (A) comparison of viable and dead cells in different DNA concentrations, (B) table shows 
the mean of viable and dead cells in different DNA concentrations. SD: standard deviation. 
 
Discussion 
Development of gene delivery systems is required 
not only in cell biology researches and clinical gene 
therapy but also in the evaluation of genes function 
analysis (19). The outcomes of DNA/RNA cargo 
delivery depend on the delivery systems for 
controlling the gene expression within any type of 
cell and function of the target genes of cargo. 
Among other factors that affect the transfer 
efficiency, including amount and type of cargo, 
timely escape of the biomolecule from endocytosis 
machinery, cell viability after transfection of 
cargo/reagent into cells, and technical aspects of 
gene delivery (1, 20, 21). The efficient amount of 
the transfection reagent and DNA/RNA cargo are 
vital matters in the transfection efficiency, as this 
study indicated that the different amounts of 
LFN3000 reagent and plasmid DNA had a 
considerable role in the high-level expression of the 
transgene and cell viability in vitro (1).  
In the present study, we performed a comparative 
analysis of the transfection efficiency of GFP 
plasmid DNA containing a CMV-promoter by 
Lipofectamine 3000 in adherent KYSE-30 cells for 
determination of the optimal DNA/LFN3000 ratio 
and cell viability. We reported the efficient transfer 
of DNA into KYSE-30 cancer cells by LFN3000 
reagents. The transfection improved with higher 
plasmid DNA concentration; although cell death 
was relatively high through LFN3000 in KYSE-30 
cells. Consequently, the high amount of plasmid 
DNA and low volume of transfection reagents 
could be an important factor for optimal 
transfection efficiency. 
Generally, lipofectamine reagents as lipid-based 
components are gold-standard systems for 
transferring DNA and siRNA/miRNA into the 
widest spectrum of cell types (22). The advantages 
of an effective transfection reagent are transgene 
delivery to more validated cell types, low toxicity, 
non-oncogenic, non-immunogenic, simplicity, 
protection against transgene degradation, high 
transfection efficiency, and no negative effects on 
downstream experiments (4, 6, 7). Lipofectamine 
3000 is a novel cationic liposome mediated-
transfection reagent with two components, 
including LFN3000 and P3000, leading to an 
efficient gene entry into the cells. According to 
numerous studies, Lipofectamine 3000 indicated 
successful nucleic acid transfer with a population of 
viable cells in various eukaryotic cell types (13, 18, 
23, 24). It has been reported that various cells can 
transfect with high efficiency using Lipofectamine 
3000, including easy and recalcitrant cells in 
transfection, such as embryonic stem cells (ESCs), 
induced pluripotent stem cells (iPSCs), primary cell 
cultures, and fibroblasts (25, 26). Lipofectamine 
3000  can apply for the transfection of cargo types, 
including plasmid DNA, shRNA, miRNA, siRNA, 
CRISPR/Cas9, and protein (24). Lipofectamine 
3000  reagents can deliver exogenous proteins like 
translation-inhibiting enzymes into the cytosol of 
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intracellular functions (27). Besides, the 
concomitant transfection of several plant 
cryptochrome linear DNAs were accomplished with 
stable transfection efficacy in HEK293T cells using 
Lipofectamine 3000 (28). Both plasmid DNA and 
siRNA were transfected to mouse embryonic stem 
cells (mESCs) by Lipofectamine 3000, resulting in 
a good transfection efficiency with siRNA-
mediated 70% downregulation (24). Furthermore, 
Cas9-mediated gene silencing in mESCs was 
performed by some transfection methods, 
suggesting good transfection efficiency by 
Lipofectamine 3000  in CRISPR-Cas9 genome 
editing (29). It has been shown that miRNA-145 
was successfully silenced using Lipofectamine 
3000  in numerous human colorectal cancer cell 
lines (HCT-8, HCT-116, SW620, SW48, LoVo, and 
HT-29) for evaluating cell invasion, proliferation, 
and migration (30). Besides, knock-out/knock-down 
experiments of various types of coding and non-
coding RNAs (PLCE1, miR503, miR543, miR107, 
PIM1, GAS5, WASH, and SIX1) were performed 
using Lipofectamine 3000  in various esophageal 
cancer cell lines (EC9706, Eca109, TE1/3/12, 
KYSE510/140/150/180/410/450, YES-2, and Het-
1A), indicating a successful transfection for 
downstream analysis (31-35). In line with the 
previous study, our results indicated good 
transfection efficiency in KYSE-30 cells with 
pCDH-513b plasmid. This data confirmed the role 
of transfection reagent and DNA cargo in the final 
efficiency of transfection. The higher and lower 
amounts of DNA and LFN3000 reagent, 
respectively, can lead to high transfection 
efficiency. The probability of success of DNA-
LFN3000 complexes delivery into cells by 
endocytosis depends on the amount of DNA 
delivered into cells. There is a direct relation 
between transfection efficacy and toxicity of 
transfection reagents based on the type of cell. The 
design of the non-viral delivery agents is based on 
increase transfection efficiency and reduces toxicity 
effects on cell viability after cargo delivery (36). 
The transfection process may lead to decreased 
living cells, increased cell death, cytotoxicity, and 
the morphological abnormalities of cells (37). 
These adverse effects can nonspecifically affect the 
expression of certain genes (38). Consequently, the 
optimization of the DNA/transfection reagents ratio 
has a critical role in the balance between the 
transfection efficiency and side effects (39). 
Transfection of single-strand oligonucleotide 
molecules like antisense oligonucleotide in different 
types of cell lines was demonstrated good 
transfection efficiency, high cytotoxicity, and 
decrees cell viability, resulting in that additional 
amounts of LFN3000 reagent may have led to side 
effects (18). Our data demonstrated that the use of 
smaller quantities of LFN3000 led to an increase in 
the percentage of GFP-expressing cells. However, it 
has been demonstrated that the transfection of 
miRNA and plasmid DNA into HEK293 cells only 
by LFN3000 reagent (without P3000 reagent) can 
reduce toxicity. Nevertheless, the usage of 
LFN3000 without P3000 reagent is usually not 
suitable for transfection efficiency (40). There are 
no studies that have evaluated the function and role 
of P3000 reagent in the transfection processes. The 
majority of previous studies have shown low 
toxicity of Lipofectamine 3000 reagents in different 
cell types. It is noteworthy that cytotoxicity and 
transfection efficiency are extremely dependent on 
cell type (13, 18, 24). Differences in cargo type and 
formulation of transfection reagents can lead to 
different levels of cytotoxicity in cells (41). Our 
results indicated that increasing the plasmid DNA 
concentration not only increased the number of 
transfected cells and the percentage of GFP-positive 
cells but also led to 59% cell death in KYSE-30. It 
has been indicated that variation at different 
concentrations of the plasmid DNA generally did 
not show a significant difference in cell viability 
and cell death, but can improve the transfection 
efficiency between 20-30% (18, 42). Consistent 
with previous studies, our results exhibited the 20-
30% increase in GFP-positive cells, very slight 
differences in average of cell death and viability at 
different DNA/LFN3000 concentrations in KYSE-
30 cells. Moreover, the cell seeding density is a key 
factor in the cargo expression and yield of 
transfection, accordingly in our study, cells were 
seeded 24 hours before transfection to reach the 
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suitable cell density (70-80% confluency) at the 
time of transfection (10). We also applied pCDH-
513b plasmid DNA under the control of the 
cytomegalovirus (CMV) promoter for DNA 
transfection. This promoter can active in the 
undifferentiated embryonic stem cells and various 
differentiated cell types (43). CMV promoter leads 
to high levels of stable and transient expression of 
cargo in different cells (44). Taken together, our 
findings consider that these reagents may not offer a 
feasible approach for gene delivery into KYSE-30 
cells and require further functional gene analysis. 
Conclusion 
In conclusion, the transfection efficiency of KYSE-
30 cells with Lipofectamine 3000 was improved 
with higher DNA concentration and a lower amount 
of LFN3000 reagent. Taken together, our findings 
revealed high transfection efficiency along with cell 
death of approximately 50% at different DNA 
concentrations. The cell type, amount of DNA, and 
LFN3000 reagent were recognized as key factors 
for prosperous transfection into KYSE-30. 
Therefore, transfection KYSE-30 cells using 
Lipofectamine 3000 need more attention for later 
analysis of genes function. 
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